Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Summary

A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts: Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three doses of either ANK-700 or placebo

Timeline

Start

2020-11-06

Primary completion

2024-04-23

Completion

2024-04-23

Publications

• Muhammad A, Xiao Y, Ahmad YM, Tang R, Zhang Y, Yuan Q, Xiao X. Reprogramming Pathogenic Immune Memory through Inverse Vaccination in Autoimmune Kidney Disease. J Am Soc Nephrol. 2026 Feb 27. doi: 10.1681/ASN.0000001070. Online ahead of print. No abstract available.

Drugs

Indications